These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35582294)

  • 1. Effect of a specific
    Manzhalii E; Moyseyenko V; Kondratiuk V; Molochek N; Falalyeyeva T; Kobyliak N
    World J Hepatol; 2022 Mar; 14(3):634-646. PubMed ID: 35582294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota.
    Wang MW; Ma WJ; Wang Y; Ma XH; Xue YF; Guan J; Chen X
    Front Microbiol; 2023; 14():1091167. PubMed ID: 37032856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
    Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
    Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence.
    Flamm SL
    Therap Adv Gastroenterol; 2011 May; 4(3):199-206. PubMed ID: 21694804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study.
    Sama C; Morselli-Labate AM; Pianta P; Lambertini L; Berardi S; Martini G
    Curr Ther Res Clin Exp; 2004 Sep; 65(5):413-22. PubMed ID: 24672094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
    Paik YH; Lee KS; Han KH; Song KH; Kim MH; Moon BS; Ahn SH; Lee SJ; Park HJ; Lee DK; Chon CY; Lee SI; Moon YM
    Yonsei Med J; 2005 Jun; 46(3):399-407. PubMed ID: 15988813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy for the treatment and prevention of hepatic encephalopathy.
    Mohammad RA; Regal RE; Alaniz C
    Ann Pharmacother; 2012 Nov; 46(11):1559-63. PubMed ID: 23092866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan.
    Chang C; Huang CH; Tseng HJ; Yang FC; Chien RN
    J Pers Med; 2021 May; 11(6):. PubMed ID: 34071787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escherichia coli Nissle 1917 Enhances Innate and Adaptive Immune Responses in a Ciprofloxacin-Treated Defined-Microbiota Piglet Model of Human Rotavirus Infection.
    Michael H; Paim FC; Langel SN; Miyazaki A; Fischer DD; Chepngeno J; Amimo J; Deblais L; Rajashekara G; Saif LJ; Vlasova AN
    mSphere; 2021 Mar; 6(2):. PubMed ID: 33789939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Luo M; Chen Y; Pan X; Chen H; Fan L; Wen Y
    Front Immunol; 2023; 14():1137089. PubMed ID: 37275915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disaccharides in the treatment of hepatic encephalopathy.
    Sharma P; Sharma BC
    Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hepatic encephalopathy in the hospital.
    Leise MD; Poterucha JJ; Kamath PS; Kim WR
    Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy for hepatic encephalopathy.
    Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
    Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
    Hayakawa Y; Tamaki N; Nakanishi H; Kurosaki M; Tanaka Y; Inada K; Ishido S; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Kaneko S; Yasui Y; Takahashi Y; Tsuchiya K; Okamoto R; Izumi N
    Intern Med; 2023 Apr; 62(7):973-978. PubMed ID: 36070941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
    Saboo K; Shamsaddini A; Iyer MV; Hu C; Fagan A; Gavis EA; White MB; Fuchs M; Heuman DM; Sikaroodi M; Iyer RK; Gillevet PM; Bajaj JS
    J Hepatol; 2021 Jan; 74(1):80-88. PubMed ID: 32679299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Variable Treatment Options in the Prevention of Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.
    Hammd M; Elghezewi A; Abdulhadi A; Alabid A; Alabid A; Badi Y; Kamal I; Hesham Gamal M; Mohamed Fisal K; Mujtaba M; Sherif A; Frandah W
    Cureus; 2024 Jan; 16(1):e53341. PubMed ID: 38435950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.